Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives.
Rebuzzi SE, Rescigno P, Catalano F, Mollica V, Vogl UM, Marandino L, Massari F, Pereira Mestre R, Zanardi E, Signori A, Buti S, Bauckneht M, Gillessen S, Banna GL, Fornarini G. Rebuzzi SE, et al. Among authors: bauckneht m. Cancers (Basel). 2022 Feb 28;14(5):1245. doi: 10.3390/cancers14051245. Cancers (Basel). 2022. PMID: 35267553 Free PMC article. Review.
18F-Facbc in Prostate Cancer: A Systematic Review and Meta-Analysis.
Laudicella R, Albano D, Alongi P, Argiroffi G, Bauckneht M, Baldari S, Bertagna F, Boero M, Vincentis G, Sole AD, Rubini G, Fantechi L, Frantellizzi V, Ganduscio G, Guglielmo P, Nappi AG, Evangelista L; on the behalf of Young AIMN Working Group. Laudicella R, et al. Among authors: bauckneht m. Cancers (Basel). 2019 Sep 11;11(9):1348. doi: 10.3390/cancers11091348. Cancers (Basel). 2019. PMID: 31514479 Free PMC article. Review.
Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223.
Bauckneht M, Capitanio S, Donegani MI, Zanardi E, Miceli A, Murialdo R, Raffa S, Tomasello L, Vitti M, Cavo A, Catalano F, Mencoboni M, Ceppi M, Marini C, Fornarini G, Boccardo F, Sambuceti G, Morbelli S. Bauckneht M, et al. Cancers (Basel). 2019 Dec 20;12(1):31. doi: 10.3390/cancers12010031. Cancers (Basel). 2019. PMID: 31861942 Free PMC article.
The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept Study.
Bauckneht M, Rebuzzi SE, Signori A, Donegani MI, Murianni V, Miceli A, Borea R, Raffa S, Damassi A, Ponzano M, Catalano F, Martelli V, Marini C, Boccardo F, Morbelli S, Sambuceti G, Fornarini G. Bauckneht M, et al. Cancers (Basel). 2020 Oct 31;12(11):3213. doi: 10.3390/cancers12113213. Cancers (Basel). 2020. PMID: 33142739 Free PMC article.
Metabolic Parameters as Biomarkers of Response to Immunotherapy and Prognosis in Non-Small Cell Lung Cancer (NSCLC): A Real World Experience.
Monaco L, Gemelli M, Gotuzzo I, Bauckneht M, Crivellaro C, Genova C, Cortinovis D, Zullo L, Ammoni LC, Bernasconi DP, Rossi G, Morbelli S, Guerra L. Monaco L, et al. Among authors: bauckneht m. Cancers (Basel). 2021 Apr 1;13(7):1634. doi: 10.3390/cancers13071634. Cancers (Basel). 2021. PMID: 33915801 Free PMC article.
The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients.
Bauckneht M, Bertagna F, Donegani MI, Durmo R, Miceli A, De Biasi V, Laudicella R, Fornarini G, Berruti A, Baldari S, Versari A, Giubbini R, Sambuceti G, Morbelli S, Albano D. Bauckneht M, et al. Prostate Cancer Prostatic Dis. 2021 Dec;24(4):1198-1207. doi: 10.1038/s41391-021-00391-8. Epub 2021 May 19. Prostate Cancer Prostatic Dis. 2021. PMID: 34012060 Free PMC article.
The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab.
Bauckneht M, Genova C, Rossi G, Rijavec E, Dal Bello MG, Ferrarazzo G, Tagliamento M, Donegani MI, Biello F, Chiola S, Zullo L, Raffa S, Lanfranchi F, Cittadini G, Marini C, Lopci E, Sambuceti G, Grossi F, Morbelli S. Bauckneht M, et al. Cancers (Basel). 2021 Jun 22;13(13):3117. doi: 10.3390/cancers13133117. Cancers (Basel). 2021. PMID: 34206545 Free PMC article.
The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study).
Bauckneht M, Rebuzzi SE, Signori A, Frantellizzi V, Murianni V, Lodi Rizzini E, Mascia M, Lavelli V, Donegani MI, Ponzano M, Gaudiano A, Stazza ML, Licari M, Cavallini L, Laghi V, Cindolo L, Maggi M, Sciarra A, Mammucci P, Sambuceti G, Costa RP, Spanu A, Rubini G, Monari F, De Vincentis G, Fornarini G. Bauckneht M, et al. Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):1063-1074. doi: 10.1007/s00259-021-05550-6. Epub 2021 Sep 6. Eur J Nucl Med Mol Imaging. 2022. PMID: 34486070 Free PMC article.
Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223.
Bauckneht M, Lai R, D'Amico F, Miceli A, Donegani MI, Campi C, Schenone D, Raffa S, Chiola S, Lanfranchi F, Rebuzzi SE, Zanardi E, Cremante M, Marini C, Fornarini G, Morbelli S, Piana M, Sambuceti G. Bauckneht M, et al. Ann Nucl Med. 2022 Apr;36(4):373-383. doi: 10.1007/s12149-022-01716-w. Epub 2022 Jan 19. Ann Nucl Med. 2022. PMID: 35044592 Free PMC article.
166 results